Subscribe to news

HSCI’S BOARD OF DIRECTORS APPROVED THE LISTS OF CANDIDATES FOR THE BOARD OF DIRECTORS AND THE AUDIT COMMISSION

Moscow – 7 March 2014.   The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced the decision of its Board of Directors on the lists of candidates to the Board of Directors and the Audit Commission of the Company to be elected at the Annual General Shareholders’ Meeting.

HSCI’s Board of Directors, following the absentee voting results, approved the list of candidates to the Board of Directors as follows:

  1. Dmitry Alexandrov, Deputy General Director for Investments, UNIVER Capital;
  2. Roman Deev, Chief Scientific Officer of HSCI;
  3. Maxim Dremin, Deputy General Director of ALOR INVEST;
  4. Vadim Zorin, General Director of Vitacel LLC;
  5. Artur Isaev, General Director of HSCI;
  6. Andrey Isaev, Director of Segment LLC;
  7. Sergey Kiselev, Head of Department at the Vavilov Institute of General Genetics of the Russian Academy of Sciences;
  8. Alexander Prikhodko, Deputy General Director of HSCI;
  9. Vladislav Saulin, General Director of High Technologies Investment Company.

According to HSCI’s Charter, the Company’s Board of Directors consists of 7 members.

HSCI’s Board of Directors also decided to include the following individuals to the list of candidates to the Audit Commission of the Company:

  1. Svetlana Blokhina, Financial Control and Internal Audit Officer of HSCI;
  2. Oksana Peterson, Deputy Chief accountant of HSCI;
  3. Svetlana Samoylova, Director for Investor Relations of HSCI.

According to HSCI’s Charter, the Company’s Audit Commission consists of 3 members.

New members of the Board of Directors and Audit Commission will be elected at the Annual General Shareholders’ Meeting of the Company upon 2013 year results.

Full Version of the Press Release (309 kb)


07 March 2014